Brokerages Expect Syndax Pharmaceuticals Inc (SNDX) Will Post Earnings of -$0.44 Per Share
Equities analysts predict that Syndax Pharmaceuticals Inc (NASDAQ:SNDX) will post earnings per share (EPS) of ($0.44) for the current quarter, according to Zacks. Two analysts have issued estimates for Syndax Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.55) and the highest estimate coming in at ($0.39). Syndax Pharmaceuticals posted earnings per share of ($0.74) during the same quarter last year, which indicates a positive year over year growth rate of 40.5%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Syndax Pharmaceuticals will report full year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($1.68). For the next financial year, analysts expect that the business will post earnings of ($2.06) per share, with EPS estimates ranging from ($2.33) to ($1.57). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Syndax Pharmaceuticals.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03. The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 107.48% and a negative net margin of 4,539.55%.
In related news, CEO Briggs Morrison bought 20,400 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $7.46 per share, for a total transaction of $152,184.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.90% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of SNDX. Raymond James & Associates purchased a new stake in Syndax Pharmaceuticals during the 4th quarter valued at about $98,000. Telemetry Investments L.L.C. grew its position in Syndax Pharmaceuticals by 116.9% during the 4th quarter. Telemetry Investments L.L.C. now owns 50,000 shares of the company’s stock worth $222,000 after purchasing an additional 26,947 shares during the last quarter. Northern Trust Corp grew its position in Syndax Pharmaceuticals by 1.6% during the 4th quarter. Northern Trust Corp now owns 175,492 shares of the company’s stock worth $781,000 after purchasing an additional 2,690 shares during the last quarter. 683 Capital Management LLC grew its position in Syndax Pharmaceuticals by 157.7% during the 4th quarter. 683 Capital Management LLC now owns 1,342,839 shares of the company’s stock worth $5,976,000 after purchasing an additional 821,839 shares during the last quarter. Finally, Morgan Stanley grew its position in Syndax Pharmaceuticals by 10.7% during the 3rd quarter. Morgan Stanley now owns 269,595 shares of the company’s stock worth $2,178,000 after purchasing an additional 26,043 shares during the last quarter. Institutional investors own 62.64% of the company’s stock.
NASDAQ:SNDX traded up $0.17 on Thursday, hitting $7.54. The stock had a trading volume of 2,338 shares, compared to its average volume of 155,298. The firm has a market cap of $204.20 million, a P/E ratio of -2.57 and a beta of 2.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.24 and a current ratio of 6.24. Syndax Pharmaceuticals has a 52 week low of $3.39 and a 52 week high of $9.15.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Read More: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.